Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 138

1.

International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis.

Díaz-González Á, Sanduzzi-Zamparelli M, Gomes da Fonseca LL, Di Costanzo GG, Alves R, Iavarone M, Leal C, Sacco R, Matilla AM, Hernández-Guerra M, Aballay Soteras G, Wörns MA, Pinter M, Varela M, Ladekarl M, Chagas AL, Mínguez B, Arenas JI, Granito A, Sánchez-Torrijos Y, Rojas Á, Rodríguez de Lope C, Alvares-da-Silva MR, Pascual S, Rimassa L, Lledó JL, Huertas C, Sangro B, Giannini EG, Delgado M, Vergara M, Perelló C, Lue A, Sala M, Gallego A, Coll S, Hernáez T, Piñero F, Pereira G, França A, Marín J, Anders M, Mello V, Lozano M, Nault JC, Menéndez J, García Juárez I, Bruix J, Reig M.

Liver Int. 2020 Mar 14. doi: 10.1111/liv.14436. [Epub ahead of print]

PMID:
32170821
2.

Recent Progress in Enzymatic Release of Peptides in Foods of Animal Origin and Assessment of Bioactivity.

Toldrá F, Gallego M, Reig M, Aristoy MC, Mora L.

J Agric Food Chem. 2020 Mar 20. doi: 10.1021/acs.jafc.9b08297. [Epub ahead of print]

PMID:
32157886
3.

Controversies in the management of hepatocellular carcinoma.

Forner A, Da Fonseca LG, Díaz-González Á, Sanduzzi-Zamparelli M, Reig M, Bruix J.

JHEP Rep. 2019 Mar 18;1(1):17-29. doi: 10.1016/j.jhepr.2019.02.003. eCollection 2019 May. Review.

4.

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models.

Cucarull B, Tutusaus A, Subías M, Stefanovic M, Hernáez-Alsina T, Boix L, Reig M, García de Frutos P, Marí M, Colell A, Bruix J, Morales A.

Cancers (Basel). 2020 Feb 1;12(2). pii: E332. doi: 10.3390/cancers12020332.

5.

Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.

Sangro B, Chan SL, Meyer T, Reig M, El-Khoueiry A, Galle PR.

J Hepatol. 2020 Feb;72(2):320-341. doi: 10.1016/j.jhep.2019.10.021. Review.

PMID:
31954495
6.

Integration of liquid-liquid membrane contactors and electrodialysis for ammonium recovery and concentration as a liquid fertilizer.

Vecino X, Reig M, Gibert O, Valderrama C, Cortina JL.

Chemosphere. 2020 Apr;245:125606. doi: 10.1016/j.chemosphere.2019.125606. Epub 2019 Dec 10.

PMID:
31855756
7.

Letter: are sorafenib-related adverse events associated with prolonged survival? Authors' reply.

Sanduzzi-Zamparelli M, Sapena V, Bruix J, Reig M.

Aliment Pharmacol Ther. 2020 Jan;51(1):192. doi: 10.1111/apt.15572. No abstract available.

PMID:
31850569
8.

Reply to: "The reported 'clear cut time association between interferon-free treatment and HCC' is anything but clear cut".

Sapena V, Rios J, Torres F, Mariño Z, Forns X, Bruix J, Reig M.

J Hepatol. 2019 Dec 13. pii: S0168-8278(19)30715-9. doi: 10.1016/j.jhep.2019.12.003. [Epub ahead of print] No abstract available.

PMID:
31843648
9.

Thermal Ablation for Intrahepatic Cholangiocarcinoma in Cirrhosis: Safety and Efficacy in Non-Surgical Patients.

Díaz-González Á, Vilana R, Bianchi L, García-Criado Á, Rimola J, Rodríguez de Lope C, Ferrer J, Ayuso C, Da Fonseca LG, Reig M, Forner A.

J Vasc Interv Radiol. 2019 Nov 1. pii: S1051-0443(19)30576-7. doi: 10.1016/j.jvir.2019.06.014. [Epub ahead of print]

PMID:
31685360
10.

Risk of recurrence of hepatocellular carcinoma in patients treated with interferon-free antivirals.

Hernáez-Alsina T, Caballol-Oliva B, Díaz-González Á, Guedes-Leal C, Reig M.

Gastroenterol Hepatol. 2019 Oct;42(8):502-511. doi: 10.1016/j.gastrohep.2019.05.003. Epub 2019 Aug 28. Review. English, Spanish.

PMID:
31472990
11.

Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.

Rimola J, Forner A, Sapena V, Llarch N, Darnell A, Díaz A, García-Criado A, Bianchi L, Vilana R, Díaz-González Á, Ayuso C, Bruix J, Reig M.

Eur Radiol. 2020 Jan;30(1):186-194. doi: 10.1007/s00330-019-06351-0. Epub 2019 Aug 1.

PMID:
31372783
12.

Insights into the success and failure of systemic therapy for hepatocellular carcinoma.

Bruix J, da Fonseca LG, Reig M.

Nat Rev Gastroenterol Hepatol. 2019 Oct;16(10):617-630. doi: 10.1038/s41575-019-0179-x. Epub 2019 Aug 1. Review.

PMID:
31371809
13.

Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation.

Iavarone M, Invernizzi F, Czauderna C, Sanduzzi-Zamparelli M, Bhoori S, Amaddeo G, Manini MA, López MF, Anders M, Pinter M, Rodríguez MJB, Cristóbal MR, Soteras GA, Piñero F, Villadsen GE, Weinmann A, Crespo G, Mazzaferro V, Regnault H, Giorgio M, González-Diéguez ML, Donato MF, Varela M, Wörns MA, Bruix J, Lampertico P, Reig M.

Am J Transplant. 2019 Nov;19(11):3176-3184. doi: 10.1111/ajt.15551. Epub 2019 Sep 3.

PMID:
31365177
14.

Reply to: "Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules - A response".

Sapena V, Rios J, Torres F, Mariño Z, Forns X, Bruix J, Reig M.

J Hepatol. 2019 Aug;71(2):447-448. doi: 10.1016/j.jhep.2019.04.018. Epub 2019 Jun 7. No abstract available.

PMID:
31182374
15.

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents.

Sanduzzi-Zamparelli M, Boix L, Leal C, Reig M.

Viruses. 2019 May 1;11(5). pii: E406. doi: 10.3390/v11050406. Review.

16.

Spontaneous Breaking of Lepton Number and the Cosmological Domain Wall Problem.

Lazarides G, Reig M, Shafi Q, Srivastava R, Valle JWF.

Phys Rev Lett. 2019 Apr 19;122(15):151301. doi: 10.1103/PhysRevLett.122.151301.

PMID:
31050531
17.

Picosecond Switchable Azo Dyes.

Garcia-Amorós J, Maerz B, Reig M, Cuadrado A, Blancafort L, Samoylova E, Velasco D.

Chemistry. 2019 Jun 7;25(32):7726-7732. doi: 10.1002/chem.201900796. Epub 2019 May 9.

PMID:
30924974
18.

Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.

Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M.

Aliment Pharmacol Ther. 2019 Mar;49(5):482-491. doi: 10.1111/apt.15088. Epub 2019 Jan 29.

PMID:
30695819
19.

Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.

Mariño Z, Darnell A, Lens S, Sapena V, Díaz A, Belmonte E, Perelló C, Calleja JL, Varela M, Rodriguez M, Rodriguez de Lope C, Llerena S, Torras X, Gallego A, Sala M, Morillas RM, Minguez B, Llaneras J, Coll S, Carrion JA, Iñarrairaegui M, Sangro B, Vilana R, Sole M, Ayuso C, Ríos J, Forns X, Bruix J, Reig M.

J Hepatol. 2019 May;70(5):874-884. doi: 10.1016/j.jhep.2019.01.005. Epub 2019 Jan 24.

PMID:
30684506
20.

Peptides with Potential Cardioprotective Effects Derived from Dry-Cured Ham Byproducts.

Gallego M, Mora L, Hayes M, Reig M, Toldrá F.

J Agric Food Chem. 2019 Jan 30;67(4):1115-1126. doi: 10.1021/acs.jafc.8b05888. Epub 2019 Jan 16.

PMID:
30648392
21.

Systemic therapy for hepatocellular carcinoma: trial enrichment does not guarantee success.

Da Fonseca LG, Reig M, Bruix J.

Oncotarget. 2018 Sep 18;9(73):33741-33742. doi: 10.18632/oncotarget.26052. eCollection 2018 Sep 18. No abstract available.

22.

New Systemic Treatments in Advanced Hepatocellular Carcinoma.

Sanduzzi-Zamparelli M, Díaz-Gonzalez Á, Reig M.

Liver Transpl. 2019 Feb;25(2):311-322. doi: 10.1002/lt.25354. Review.

23.

Evaluating the response to locoregional and systemic treatment for hepatocellular carcinoma.

Darnell A, Belmonte E, Reig M, Brú C.

Radiologia. 2018 Sep - Oct;60(5):424-436. doi: 10.1016/j.rx.2018.05.004. Epub 2018 Jul 6. English, Spanish.

24.

Should Patients With NAFLD/NASH Be Surveyed for HCC?

Reig M, Gambato M, Man NK, Roberts JP, Victor D, Orci LA, Toso C.

Transplantation. 2019 Jan;103(1):39-44. doi: 10.1097/TP.0000000000002361. Review.

PMID:
30080818
25.

Generation of bioactive peptides during food processing.

Toldrá F, Reig M, Aristoy MC, Mora L.

Food Chem. 2018 Nov 30;267:395-404. doi: 10.1016/j.foodchem.2017.06.119. Epub 2017 Jun 21. Review.

26.

Erratum to «Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline» [Gastroenterol Hepatol. 2018;41(5):328-349].

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, López Miranda J, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego-Durán R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.

Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476. doi: 10.1016/j.gastrohep.2018.05.011. English, Spanish. No abstract available.

PMID:
29929828
27.

Interface engineering and solid-state organization for triindole-based p-type organic thin-film transistors.

Reig M, Bagdziunas G, Ramanavicius A, Puigdollers J, Velasco D.

Phys Chem Chem Phys. 2018 Jul 4;20(26):17889-17898. doi: 10.1039/c8cp02963f.

PMID:
29926056
28.

Systemic therapy for intermediate and advanced hepatocellular carcinoma: Sorafenib and beyond.

Raoul JL, Kudo M, Finn RS, Edeline J, Reig M, Galle PR.

Cancer Treat Rev. 2018 Jul;68:16-24. doi: 10.1016/j.ctrv.2018.05.006. Epub 2018 May 26. Review.

29.

A study of the properties, reactivity and anticancer activity of novel N-methylated-3-thiazolyl or 3-thienyl carbazoles and their Pd(II) and Pt(II) complexes.

Reig M, Bosque R, Font-Bardía M, Calvis C, Messeguer R, Baldomà L, Badía J, Velasco D, López C.

J Inorg Biochem. 2018 Jul;184:134-145. doi: 10.1016/j.jinorgbio.2018.03.008. Epub 2018 Mar 15. No abstract available.

PMID:
29751214
30.

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.

Tutusaus A, Stefanovic M, Boix L, Cucarull B, Zamora A, Blasco L, de Frutos PG, Reig M, Fernandez-Checa JC, Marí M, Colell A, Bruix J, Morales A.

Oncotarget. 2018 Mar 30;9(24):16701-16717. doi: 10.18632/oncotarget.24673. eCollection 2018 Mar 30.

31.

New trials and results in systemic treatment of HCC.

Reig M, da Fonseca LG, Faivre S.

J Hepatol. 2018 Aug;69(2):525-533. doi: 10.1016/j.jhep.2018.03.028. Epub 2018 Apr 11. Review.

PMID:
29653122
32.

Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline.

Aller R, Fernández-Rodríguez C, Lo Iacono O, Bañares R, Abad J, Carrión JA, García-Monzón C, Caballería J, Berenguer M, Rodríguez-Perálvarez M, Miranda JL, Vilar-Gómez E, Crespo J, García-Cortés M, Reig M, Navarro JM, Gallego R, Genescà J, Arias-Loste MT, Pareja MJ, Albillos A, Muntané J, Jorquera F, Solà E, Hernández-Guerra M, Rojo MÁ, Salmerón J, Caballería L, Diago M, Molina E, Bataller R, Romero-Gómez M.

Gastroenterol Hepatol. 2018 May;41(5):328-349. doi: 10.1016/j.gastrohep.2017.12.003. Epub 2018 Apr 7. English, Spanish. Erratum in: Gastroenterol Hepatol. 2018 Aug - Sep;41(7):475-476.

PMID:
29631866
33.

Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.

Rimassa L, Assenat E, Peck-Radosavljevic M, Pracht M, Zagonel V, Mathurin P, Rota Caremoli E, Porta C, Daniele B, Bolondi L, Mazzaferro V, Harris W, Damjanov N, Pastorelli D, Reig M, Knox J, Negri F, Trojan J, López López C, Personeni N, Decaens T, Dupuy M, Sieghart W, Abbadessa G, Schwartz B, Lamar M, Goldberg T, Shuster D, Santoro A, Bruix J.

Lancet Oncol. 2018 May;19(5):682-693. doi: 10.1016/S1470-2045(18)30146-3. Epub 2018 Apr 3.

PMID:
29625879
34.

Lenvatinib: can a non-inferiority trial change clinical practice?

Reig M, Bruix J.

Lancet. 2018 Mar 24;391(10126):1123-1124. doi: 10.1016/S0140-6736(18)30208-3. Epub 2018 Feb 9. No abstract available.

PMID:
29433849
35.

Stability of the potent antioxidant peptide SNAAC identified from Spanish dry-cured ham.

Gallego M, Mora L, Reig M, Toldrá F.

Food Res Int. 2018 Mar;105:873-879. doi: 10.1016/j.foodres.2017.12.006. Epub 2017 Dec 5.

36.

Hepatocellular carcinoma.

Forner A, Reig M, Bruix J.

Lancet. 2018 Mar 31;391(10127):1301-1314. doi: 10.1016/S0140-6736(18)30010-2. Epub 2018 Jan 5. Review.

PMID:
29307467
37.

The success of regorafenib in hepatocellular carcinoma in a world of failures. Learnings for future developments.

Reig M, Díaz-González Á, Bruix J.

Oncotarget. 2017 Nov 11;8(63):106151-106152. doi: 10.18632/oncotarget.22382. eCollection 2017 Dec 5. No abstract available.

38.

Solid-state organization of n-type carbazole-based semiconductors for organic thin-film transistors.

Reig M, Puigdollers J, Velasco D.

Phys Chem Chem Phys. 2018 Jan 3;20(2):1142-1149. doi: 10.1039/c7cp05135b.

PMID:
29239425
39.

Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events.

Rimola J, Díaz-González Á, Darnell A, Varela M, Pons F, Hernandez-Guerra M, Delgado M, Castroagudin J, Matilla A, Sangro B, Rodriguez de Lope C, Sala M, Gonzalez C, Huertas C, Minguez B, Ayuso C, Bruix J, Reig M.

Hepatology. 2018 Feb;67(2):612-622. doi: 10.1002/hep.29515. Epub 2018 Jan 2.

40.

Effect of cooking and in vitro digestion on the antioxidant activity of dry-cured ham by-products.

Gallego M, Mora L, Hayes M, Reig M, Toldrá F.

Food Res Int. 2017 Jul;97:296-306. doi: 10.1016/j.foodres.2017.04.027. Epub 2017 Apr 25.

PMID:
28578055
41.

Tumor biopsy and patient enrollment in clinical trials for advanced hepatocellular carcinoma.

Rimassa L, Reig M, Abbadessa G, Peck-Radosavljevic M, Harris W, Zagonel V, Pastorelli D, Rota Caremoli E, Porta C, Damjanov N, Patel H, Daniele B, Lamar M, Schwartz B, Goldberg T, Santoro A, Bruix J.

World J Gastroenterol. 2017 Apr 7;23(13):2448-2452. doi: 10.3748/wjg.v23.i13.2448.

42.

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

Reig M, Boix L, Mariño Z, Torres F, Forns X, Bruix J.

Semin Liver Dis. 2017 May;37(2):109-118. doi: 10.1055/s-0037-1601349. Epub 2017 Apr 7. Review.

PMID:
28388736
43.

Assessment of treatment efficacy in hepatocellular carcinoma: Response rate, delay in progression or none of them.

Bruix J, Reig M, Sangro B.

J Hepatol. 2017 Jun;66(6):1114-1117. doi: 10.1016/j.jhep.2017.02.032. Epub 2017 Mar 9. No abstract available.

PMID:
28284917
44.

Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers.

Rodríguez de Lope C, Reig M, Matilla A, Ferrer MT, Dueñas E, Mínguez B, F Castroagudín J, Ortiz I, Pascual S, Lledó JL, Gallego A, Arenas JI, Aracil C, Forne M, Muñoz C, Pons F, Sala M, Iñarrairaegui M, Martin-Llahi M, Andreu V, Garre C, Rendón P, Fuentes J, Crespo J, Rodríguez M, Bruix J, Varela M; en representación del Grupo de Estudio de Cáncer Hepático (GECH).

Med Clin (Barc). 2017 Jul 21;149(2):61-71. doi: 10.1016/j.medcli.2016.12.048. Epub 2017 Mar 7. English, Spanish.

PMID:
28279536
45.

Tuning the ambipolar charge transport properties of tricyanovinyl-substituted carbazole-based materials.

Reig M, Bagdziunas G, Volyniuk D, Grazulevicius JV, Velasco D.

Phys Chem Chem Phys. 2017 Mar 1;19(9):6721-6730. doi: 10.1039/c6cp08078b.

PMID:
28210730
46.

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma.

Reig M, Boix L, Bruix J.

Liver Int. 2017 Jan;37 Suppl 1:136-139. doi: 10.1111/liv.13321. Review.

PMID:
28052619
47.

Stable All-Organic Radicals with Ambipolar Charge Transport.

Reig M, Gozálvez C, Jankauskas V, Gaidelis V, Grazulevicius JV, Fajarí L, Juliá L, Velasco D.

Chemistry. 2016 Dec 19;22(51):18551-18558. doi: 10.1002/chem.201603723. Epub 2016 Nov 7.

PMID:
27706851
48.

Systemic treatment for advanced hepatocellular carcinoma: the search of new agents to join sorafenib in the effective therapeutic armamentarium.

Ribeiro de Souza A, Reig M, Bruix J.

Expert Opin Pharmacother. 2016 Oct;17(14):1923-36. doi: 10.1080/14656566.2016.1225722. Review.

PMID:
27598745
49.

Treatment of Hepatocellular Carcinoma.

Díaz-González Á, Reig M, Bruix J.

Dig Dis. 2016;34(5):597-602. doi: 10.1159/000445275. Epub 2016 Jun 22. Review.

PMID:
27332893
50.

Reply to "Direct antiviral agents and risk for hepatocellular carcinoma (HCC) early recurrence: Much ado about nothing".

Reig M, Torres F, Mariño Z, Forns X, Bruix J.

J Hepatol. 2016 Oct;65(4):864-865. doi: 10.1016/j.jhep.2016.05.036. Epub 2016 May 30. No abstract available.

PMID:
27255581

Supplemental Content

Support Center